



A Pan-Canadian Core Dataset for Rheumatoid Arthritis

**Thursday, October 27th, 2016, 8:00 am-10:00 am
InterContinental Hotel, Montreal**

1. GETTING STARTED:

- a) Welcome and Introduction
- b) Meeting Objectives/Session Overview

Dr. Dianne Mosher

Division Chief of Rheumatology, Department
of Medicine, University of Calgary, AB

Session Objectives

A Pan-Canadian Core Clinical Dataset for Rheumatoid Arthritis

- Review work from the Core Clinical Dataset Models of Care work group. Including an update on testing of the System-Level Performance Measures for IA and expansion of the measurement framework to include provider-level process measures and patient outcomes. This work provides context for the importance of the current project: Development of a Pan-Canadian Core Clinical Dataset for RA
- Review and discussion of the proposed Pan-Canadian Core Clinical Dataset for RA
- Provincial examples and discussion of the incorporation of the core clinical dataset into practice

Today's Agenda

Item	Presenter
1. Getting Started <ul style="list-style-type: none"> a) Welcome and introduction b) Meeting objectives/session overview 	Dr. Dianne Mosher
2. Context: What do we know and why is it important to clinical practice? <ul style="list-style-type: none"> a) Project background, lessons learned b) System Level Performance Measurement Framework update c) Provider level key performance indicators: Literature review 	Dr. Claire Barber
3. A Pan-Canadian Core Clinical Dataset for inclusion in a quality measurement framework <ul style="list-style-type: none"> a) Review of proposed core clinical dataset for RA b) OBRI/Fig P Core Variable EMR Data Extraction Pilot 	Dr. Claire Barber Dr. Vandana Ahluwalia
4. Provincial roundtable: Provincial champions share how they will incorporate the core dataset into their practice	Facilitated by Dr. Michel Zumner
5. Wrap up and next steps	Dr. Cheryl Barnabe

AAC IA Model of Care Executive Team

Co-Chairs:

1. **Dr. Vandana Ahluwalia**, Vice-President, Canadian Rheumatology Association; Corporate Chief of Rheumatology, William Osler Health System, Brampton, ON
2. **Dr. Dianne Mosher**, Professor of Medicine, Chief Division of Rheumatology, University of Calgary, Calgary, AB
3. **Dr. Michel Zummer**, Chief of Rheumatology, CH Maisonneuve-Rosemont; Associate Professor, Université de Montréal, Montreal, QC


Dr. Claire Barber, Rheumatologist, Division of Rheumatology, University of Calgary, AB

Dr. Cheryl Barnabe, Chair, Access to Care Committee, Canadian Rheumatology Association


Ms. Anne Lyddiatt, Patient Representative, Ingersoll, ON

Improving Prevention and Care

Access to and Delivery of Care **Models of Care (MoC)**



Pan-Canadian IA MoC: Development, Dissemination and Measurement



A Pan-Canadian Approach to Inflammatory Arthritis Models of Care

Purpose

- Establish a framework for the development of high quality models of care that are evidence informed and reinforced by best practices.

Users

- Health policy decision-makers and system planners; rheumatologists, allied health providers and other primary care providers; and, people living with arthritis.

A pan-Canadian Approach to Inflammatory Arthritis Models of Care




April, 2014

AAC
Arthritis Alliance of Canada
Alliance de l'arthrite du Canada


Toolkit for Implementation: Standardized IA Care Map

- ❑ The pan-Canadian report describes the approach to the delivery of care and is accompanied by a drop **down menu** care map/toolkit for implementation.
- ❑ The Care Map illustrates the flow of patients through the continuum of care, to ensure the patient has access to the **right** care provider at the **right** time in the care path.


Rheumatoid Arthritis Care Map



Inflammatory Arthritis Care Map



Pan-Canadian Approach to IA MoC: 6 Key Elements




2. Context: What do we know and why is it important to clinical practice?

- a) Project background, lessons learned
- b) System-Level Performance Measurement update
- c) Systematic Review of Provider Level Measures

Dr. Claire Barber

Rheumatologist, Division of Rheumatology,
University of Calgary, AB

Measuring a Model of Care for Inflammatory Arthritis



Testing Performance Measures: Update

- Testing of the measures in 5 provinces (BC, AB, MB, NL, ON) in 11 different arthritis care settings using different data sources (e.g., administrative data, early arthritis cohort, early arthritis clinics, EMR)
- CATCH data analysis nearly complete. To be presented at ACR Nov 16th 9AM (#3137) “Assessing System-Level Performance Measures for Early RA in a Large Multicenter Cross-Country Prospective 8-Year Observational Cohort Study.”
- Waiting Time data from 3 centers analyzed and a CRA abstract has been submitted
- Ethics approval at all sites has been obtained, data for administrative analysis obtained at all sites with plans to start analysis shortly



CATCH Data Highlights

See Barber CEH et al. *Arthritis Rheumatol.* 2016; 68 (suppl 10).

<http://acrabstracts.org/abstract/assessing-system-level-performance-measures-for-early-rheumatoid-arthritis-in-a-large-multicenter-cross-country-prospective-8-year-observational-cohort-study/>. Accessed October 20, 2016

Catch Lessons

- Represents "Best-Case" scenario and will be useful for benchmarking
 - Delays in referral not captured so waiting times could not be measured
 - Decline in follow-up and DMARD use over time need further exploration
 - Currently working on different methods of operationalizing measures to avoid confounding by duration of disease
-

Waiting Time: Lessons in Feasibility of Measurement

- WTs for RA measured in 5 models of care in 3 provinces for 2014/15
- All sites required chart reviews (even those with triage databases as lacking diagnosis and/or date seen by rheumatologist)
- WTs could not be readily measured in 2 sites that offered self-referral to indigenous communities
- Large regional variations noted in WTs, only one center meeting benchmarks.... Stay tuned.

Measurement Framework Expansion

- Current AAC measurement framework does not capture measures at physician-provider level or patient outcomes
 - CIHR grant submitted to develop a balanced scorecard for RA care:
 - Objective to measure and report on RA quality measures for continuous improvement
 - First step: Systematic Review to Identify Existing measures
-

Systematic Review

- See Barber CEH et al. *Arthritis Rheumatol.* 2016; 68 (suppl 10).
<http://acrabstracts.org/abstract/assessing-system-level-performance-measures-for-early-rheumatoid-arthritis-in-a-large-multicenter-cross-country-prospective-8-year-observational-cohort-study/>.
Accessed October 20, 2016

Next Steps: Balanced Scorecard



Link to Core Dataset

- Data needed to measure quality of care
- Currently no consistent recommendations about what data to routinely collect on patients for provision of routine care and quality assurance



3. A Pan-Canadian Core Clinical Dataset for Inclusion in a Quality Measurement Framework

a) Review of proposed core clinical dataset for

Dr. Claire Barber

Rheumatologist, Division of Rheumatology,
University of Calgary, AB


A Standardized Pan-Canadian Core Clinical Dataset for Inclusion in a Quality Measurement Framework

The Need

- Utilizing EMR's and existing databases can drive quality improvements in care but data collected is not standardized.
Also, duplication of data collection for research purposes is costly and a burden on healthcare providers and patients.

The Vision


- A standardized, rheumatology specific core clinical dataset to mitigate variability in data collection and result in high quality data that is comparable between physicians, sites and provinces.



What is a “core dataset”

- **The minimal dataset needed to provide high-quality care for patients with arthritis**
 - Should reflect what is done (or *should* be done) in practice
 - Enhance and facilitate efforts for quality measurement
 - A benefit to research but not the primary reason for collection

Methods Developing a Pan-Canadian Core Clinical Dataset



Delphi

- Participants asked to rate 2 questions about each element on a Likert scale of 1-9 (1= not important/feasible and 9=very important/feasible)
- *How important is it to include this element in the core data set for the provision of care and clinical decision making for RA?*
- *How feasible is it to collect this element routinely on patients with RA?*



Core Dataset Next Steps



AAC Pan-Canadian Core Clinical Dataset Working Group

Dr. Vandana Ahluwalia
Dr. Stephen Aaron
Dr. Antonio Avina-
Zubieta
Dr. Claire Barber
Dr. Murray Baron
Dr. Cheryl Barnabe
Dr. Susanne Benseler
Dr. Louis Bessette
Dr. Claire Bombardier
Ms. Jennifer Burt
Dr. Denis Choquette
Dr. Vinod Chandran
Dr. Alex Charlton

Dr. Mathew Cooper
Ms. Sandra Couto
Ms. Andrea Emrick
Dr. Stephen Edworthy
Dr. Hani El-Gabalawy
Dr. Jaime Guzman
Dr. Jill Hall
Dr. Linda Hiraki
Dr. Joanne Homik
Dr. Steven Katz
Dr. Stephanie Keeling
Dr. Jason Kur
Dr. Dianne Lacaille
Dr. Deborah Levy
Ms. Anne Lyddiatt

Ms. Terri Lupton
Dr. Deborah Marshall
Dr. Dianne Mosher
Dr. Bindu Nair
Dr. Sylvie Ouellette
Dr. Namneet Sandhu
Ms. Orit Schieir
Dr. Evelyn Sutton
Dr. Regina Taylor-Gjevre
Dr. Carter Thorne
Dr. Marinka Twilt
Dr. John Woolcott
Dr. Michel Zumner




b) OBRI/Fig P Core Variable EMR Data Extraction Pilot

Dr. Vandana Ahluwalia

**On behalf of the OBRI Investigators and Dr.
Claire Bombardier**

Corporate Chief of Rheumatology, William Osler
Health System, Brampton, ON




OBRI /Fig P Core Variable EMR Data Extraction Pilot

**Dr. Vandana Ahluwalia
AAC Annual Conference
October 27 2016**

Created in 2008, the OBRI is a collaboration of stakeholders, representing rheumatologists, patients, researchers, payers.

The OBRI focused on improving the quality of care and clinical outcomes of patients living with Rheumatoid Arthritis by gathering long-term information on the therapies used in daily clinical practice



We are linking real-world data

CLINICAL COHORT

PHYSICIAN REPORTED

- Personal Health Information
- RA History
- Previous RA medications
- Physician Global Assessment
- Patient Global Assessment
- Co-morbidities
- Serious Events
- Laboratory (ESR, CRP)
- Tender Joint Count
- Swollen Joint Count
- Erosions
- Current RA Medications

PATIENT REPORTED

- Demographics
- RA History
- Previous Anti-rheumatic Medications
- Current Medication
- HAQ / RADA
- Patient Global Assessment/Q of L
- Fatigue And Sleep
- Socio-economic Status
- Work Productivity
- Serious Events / Tuberculosis
- Pregnancy
- Pharmacy/Labs/Imaging



investigators



patients

ADMINISTRATIVE DATABASE LINKAGE*

SERIOUS ADVERSE EVENTS

- Fatal
- Life-threatening
- Hospital stay
- Significant disability
- Congenital anomaly
- Serious Infections
- Congestive heart failure
- Central Demyelination
- Aplastic anemia
- Lymphoproliferative tumors
- Autoimmune disease
- Hepatotoxicity death

HEALTH SERVICES USED

- Drug information
- Physician claims
- Diagnostic tests
- Patient demographics
- Hospitalizations
- Cancer registry
- Home Care service use

* Lifelong


Participating Investigators (RA)

Dr. Vandana Ahluwalia
Dr. Zareen Ahmad
Dr. Pooneh Akhavan
Dr. Lori Albert
Dr. Catherine Alderdice
Dr. Michael Aubrey
Dr. Sangeeta Bajaj
Dr. Bill Bensen
Dr. Claire Bombardier
Dr. Arthur Bookman
Dr. Doreen Campbell
Dr. Simon Carette
Dr. Raj Carmona
Dr. Dana Cohen
Dr. Patricia Ciaschini
Dr. Alf Cividino
Dr. Andrew Chow
Dr. Sanjay Dixit
Dr. Darek Haaland
Dr. Brian Hanna
Dr. Nigil Haroon

Dr. Jackie Hochman
Dr. Anna Jaroszynska
Dr. Sindu Johnson
Dr. Raman Joshi
Dr. Allan Kagal
Dr. Arthur Karasik
Dr. Jacob Karsh
Dr. Nader Khalidi
Dr. Ed Keystone
Dr. Bindee Kuriya
Dr. Maggie Larche
Dr. Arthur Lau
Dr. Nicole Leriche
Dr. Felix Leung
Dr. Frances Leung
Dr. Dharni Mahendra
Dr. Mark Matsos
Dr. Heather McDonald
Blumer
Dr. Shikha Mittoo
Dr. Ami Mody
Dr. Angela Montgomery

Dr. Manisha Mulgund
Dr. Edward Ng
Dr. Erin Norris
Dr. Tripti Papneja
Dr. Viktoria Pavlova
Dr. Louise Perlin
Dr. Janet Pope
Dr. Jane Purvis
Dr. Gina Rohekar
Dr. Sherri Rohekar
Dr. Lawrence Rubin
Dr. Nooshin Samadi
Dr. Saeed Shaikh
Dr. Ali Shickh
Dr. Rachel Shupak
Dr. Elaine Soucy
Dr. Doug Smith
Dr. Jonathan Stein
Dr. Andy Thompson
Dr. Carter Thorne
Dr. Sharon Wilkinson

Ontario Rheumatologists have adopted EMRs



Over **93%** of community
Rheumatologists
in Ontario are using EMR
Highest among specialty groups
Supported by OMD and the ORA

Academic rheumatologists
pending EMR selection by their hospitals


2015

Phase III- pilot .
Working towards
seamless data
extraction



Can we seamlessly extract clinical data from Ontario Rheumatology EMRs?

(a self-funded leadership initiative)





Rationale for EMR Pilot

- ❖ The OBRI took a leadership role to explore how clinical data could be extracted from clinicians EMRs seamlessly and for meaningful use – for both quality improvement and research purposes



To Develop a secure central repository web based platform

1

Development

Design, develop and validate by pilot-testing an automated, secure, and scalable data fetch and transfer process for OBRI participants

3

- **Retrieval by OBRI**
- For OBRI staff to securely retrieve data batches

2

- **Central Repository**
- Directly complete or edit data in the central repository (by EMR participants)
- Directly enter and submit data to the central repository (by non-EMR participants)

4

- **Review by Users**
- Overview participant's accumulating registry data (dashboards)

OBRI's EMR Project Partnerships



FIG P
Serving the specialized Data
Management needs of
Clinicians and Scientists
since 1988



ORA-
Representing Ontario
Rheumatologists and
focused on Arthritis care in
Ontario through Leadership,
Advocacy, Education and
Communications

Pilot Participants



EMR Pilot Dec 2015- October 2016

Data extraction Accuro

- Dr. Vandana Ahluwalia
- Dr. Carter Thorne
- Dr. Derek Haaland
- Dr. Art Karasik

Completed

Data Extraction EPIC

- Women's College (EPIC)

On HOLD

Web based

- Ottawa General Hospital and non-EMR sites

Pending Ethics

Oscar and Telus PS in Phase 2



OBRI Data Variables

CLINICAL OUTCOME DATA (collected by MD)	PERSONAL HEALTH INFORMATION	INTERVIEW DATA
TJC SJC Patient Global MD Global ESR CRP RA Medication Names RA Medication Start/Stop Dates	Name Gender Date of Birth Telephone Number Address OHIP Number	HAQ RADAI RA Medication Names RA Medication Start/Stop Dates Previous RA Medications Co-morbidities Work Productivity Socioeconomic Status

The data variables that were included in the EMR pilot



Data extraction Project

- FigP identified OBRI participants in EMRs
- The results were compared to what is currently available at OBRI
- Data extraction was based on the 3 OBRI case report forms:
 1. Enrollment
 2. Assessment
 3. Medication

Results: Enrollment Form

Table 2. Agreement Between Fig.P Extracted Data and OBRI Data, by Site










Variable	Site 1 (n = 35)	Site 2 (n = 21)	Site 3 (n = 13)	Site 4 (n = 38)
Health Card No.	97%	100%	100%	97%
Anti-CPP	40%	19%		34%
Rheumatoid Factor	43%	52%		45%
RA Duration (yr of diagnosis)	27%	0		5%

Results: **Assessment Forms**

Table 3. Agreement Between Fig.P Extracted Data and OBRI Data, by Site

Variable	Site 1 (n = 705)	Site 2 (n = 395)	Site 3 (n = 83)	Site 4 (n = 95)
Physician Global	93%	63%		34%
Patient Global	82%	58%		35%
Total Tender Joints	94%	56%		90%
Total Swollen Joints	94%	65%		85%
ESR Value	87%	72%		54%
CRP Value	78%	67%		48%

Summary of Data Extraction

Data Domain	Results	Notes
Demographics		
OBRI “active” patients		Need for site training for consistent standardize
Visit dates		
Medical history / co- morbidities		Dates cannot be extracted Need for site training to populate in CPP
Lab results: RF, anti-CCP, ESR, CRP		Need for site training to populate in CPP(Rf, anti- ccp)
Physical findings / Standard scores: 28-TJC, 28-SJC, Pt GA, MD GA		No joints can be extracted individually Need for site training to populate in CPP(globals)
X-ray results: re: Erosions	 	Dates cannot be extracted Need for site training to populate in CPP
Medications: Prescribed / Started, Discontinued / Stopped	 “DMARDs”: Name “Current Rheum Meds”: Name “Rx meds”: Name Name only	Need for site training to retrieve start, stop dates

Collaborations & Partnerships

- Work with OMD and EMR vendors to improved extraction of medications
- Leverage the work of the Arthritis Alliance of Canada to identify a minimum clinical core data set for extraction
- Partner with ORA to create messaging and advocacy for meaningful use of EMR data
 1. Benefits of seamless data extraction for members
 2. Tools/guides to expedite population of members' CPP – this way data can be easily extracted from EMR
 3. Quality Improvement and Dashboards for members – individual vs cohort
 4. Source of real world data for payers and the pan- Canadian Pharmaceutical Alliance





Next steps

- Expand data extraction work for OBRI Investigators that use Oscar or Telus-PS EMRs
- Direct non EMR sites to use Web based interface
- Develop rheumatology dashboards
- Explore new funding model



4. PROVINCIAL ROUNDTABLE

Provincial champions share how they will incorporate the core dataset into their practice

Dr. Michel Zummer

Division Chief of Rheumatology, CH
Maisonnette-Rosemont, Associate Professor,
Université de Montréal, QC

Provincial Model of Care champions

5. WRAP UP AND NEXT STEPS

Dr. Cheryl Barnabe

Associate Professor, Departments of
Medicine and Community Health Sciences,
University of Calgary
Rheumatologist, Alberta Health Services

A Pan-Canadian Core Clinical Dataset

– next steps

Phase 1: Environmental scan – complete

Assess the current status of data collection in Canada



Phase 2: Development of a Canadian core dataset - in progress

Generate a core clinical dataset for rheumatology

Phase 3: Systematic Review of Quality Measures in IA -complete

Conduct a systematic review of quality measures in IA



Phase 4: Patient engagement-ongoing

Ensure variables important to patients are included in the dataset and framework.

Phase 5: Mapping of dataset variables and core clinical datasets (clinic and research)

Phase: 6 Consensus complete-complete

A 3 round modified Delphi will review any areas of debate to achieve consensus on the dataset.



Phase 7: Development of tools for implementation and dissemination of the program

Create tools for implementation of the common dataset for effective knowledge translation.

End of Session

If you have any questions or would like to follow-up on any topic on today's agenda, please contact Jaime Coish at jcoish@arthritisalliance.ca or visit our website www.arthritisalliance.ca

